Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer
Introduction Immune checkpoint inhibitors (ICI) are now utilized as a standard of care
treatment for multiple cancers, including in both the metastatic setting as well as in earlier …
treatment for multiple cancers, including in both the metastatic setting as well as in earlier …
[HTML][HTML] Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international …
NM Chanza, W Xie, M Issa, H Dzimitrowicz… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background There is limited experience regarding the safety and efficacy of checkpoint
inhibitors (CPI) in patients with autoimmune disorders (AD) and advanced urological …
inhibitors (CPI) in patients with autoimmune disorders (AD) and advanced urological …
[HTML][HTML] Update of a prognostic survival model in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors using an expansion …
M Issa, BG Klamer, N Mladkova, GI Laliotis, V Karivedu… - BMC cancer, 2022 - Springer
Background Immune checkpoint inhibitors (ICI) treatment in recurrent/metastatic (R/M) head
and neck squamous cell carcinoma (HNSCC) offers new therapeutic venues. We have …
and neck squamous cell carcinoma (HNSCC) offers new therapeutic venues. We have …
Use of cetuximab added to weekly chemotherapy to improve progression-free survival in patients with recurrent metastatic head and neck squamous cell carcinoma …
M Issa, B Klamer, V Karivedu, P Bhateja, GI Laliotis… - 2021 - ascopubs.org
6038 Background: Immune checkpoint inhibitors (ICI) are currently approved in the
treatment of patients (pts) with recurrent-metastatic (R/M) head and neck squamous cell …
treatment of patients (pts) with recurrent-metastatic (R/M) head and neck squamous cell …
Definitive chemoradiotherapy with carboplatin for squamous cell carcinoma of the head and neck
M Nagasaka, M Zaki, M Issa, H Kim… - The …, 2017 - Wiley Online Library
Objective Definitive concurrent chemoradiotherapy (CRT) is considered the standard of care
for organ preservation and is the only potentially curative therapy for surgically unresectable …
for organ preservation and is the only potentially curative therapy for surgically unresectable …
[HTML][HTML] Calcitriol-mediated hypercalcemia as an immune-related adverse event in a patient receiving nivolumab and ipilimumab for metastatic renal cell carcinoma …
K Johnson, M Issa, A Parikh, P Monk, M Yin… - BMC urology, 2021 - Springer
Background Severe hypercalcemia is often associated with uncontrolled malignancy
through several mechanisms. However, calcitriol-mediated hypercalcemia is a rare etiology …
through several mechanisms. However, calcitriol-mediated hypercalcemia is a rare etiology …
Treatment outcomes of head and neck cancer patients in the elderly receiving different chemoradiation combinations: a single-center experience
V Karivedu, M Bonomi, M Issa, A Blakaj… - Oncology Research …, 2021 - karger.com
Objectives: This study aimed to assess the effect of definitive or adjuvant concurrent
chemoradiation (CRT) among elderly patients with locally advanced head and neck …
chemoradiation (CRT) among elderly patients with locally advanced head and neck …
Impact of Tobacco, Marijuana and Alcohol Use on Overall Survival in Recurrent Metastatic Head and Neck Cancer Patients Treated with Immune Checkpoint Inhibitors
M Issa, M Husain, B Klamer, G Laliotis… - International Journal of …, 2022 - redjournal.org
Purpose/Objective (s) Tobacco, marijuana, and alcohol use have all been associated with
immune suppressive effect. This study assess the impact of smoking status, marijuana use …
immune suppressive effect. This study assess the impact of smoking status, marijuana use …
Clinical course of hypertrophic pulmonary osteoarthropathy in a patient receiving immune checkpoint inhibitor therapy
AC Johns, C Sorenson, A Rogers, JL Agne… - Clinical lung cancer, 2020 - Elsevier
Hypertrophic pulmonary osteoarthropathy (HPOA) is a well-known paraneoplastic syndrome
associated with lung cancer, and some have hypothesized that its pathophysiology is …
associated with lung cancer, and some have hypothesized that its pathophysiology is …
[HTML][HTML] Weekly vs. 3‑weekly paclitaxel, carboplatin, and cetuximab (PCC) in recurrent/metastatic head and neck cancer
L Geraghty, TE Schultz… - Molecular and …, 2021 - spandidos-publications.com
The combination of paclitaxel, carboplatin and cetuximab (PCC) is efficacious in patients
with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) …
with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) …